Use of 2,3,2-tetramine as a hepatic copper chelating agent for treatment of copper hepatotoxicosis in Bedlington terriers.
Five Bedlington Terriers with inherited copper (Cu) hepatotoxicosis and with hepatic Cu concentrations ranging from 3,000 to 11,000 micrograms/g of dry weight (normal, less than 350 micrograms/g of dry weight) were treated daily for up to 200 days with 2,3,2-tetramine tetrahydrochloride. During treatment, no change was made in the dietary Cu intake, which ranged from 12 to 16 micrograms/g of dry diet. Concentrations of hepatic and serum Cu, iron, and zinc were determined before and at the conclusion of the treatment period. In one dog, 24-hour urinary Cu concentration was measured before and during treatment. A liver biopsy specimen obtained after treatment had significantly (P less than 0.05) reduced hepatic Cu concentration (3,282 micrograms/g of dry weight; a 54.9% reduction), compared with the pretreatment value (7,281 micrograms/g of dry weight). After treatment, there was an overall general lessening of the extent of hepatic morphologic damage. Cytochemical examination for Cu in rhodanine-stained biopsy specimens revealed decreased numbers of Cu-laden hepatic lysosomes. The mean daily urinary Cu concentration increased as much as 25-fold during 2,3,2-tetramine treatment. Hepatic iron and zinc concentrations and serum Cu concentrations remained within normal ranges after treatment. Clinical or laboratory evidence of 2,3,2-tetramine toxicosis was not detected during treatment. These findings indicated that in affected Bedlington Terriers, 2,3,2-tetramine was a safe and rapid chelating agent of hepatic Cu.
Twedt
D C
DC
Department of Clinical Sciences, Colorado State University, Fort Collins 80523.
Hunsaker
H A
HA
Allen
K G
KG
D000818:Animals; D003300:Copper / Q000032:analysis / Q000097:blood / Q000378:metabolism*; D004283:Dog Diseases / Q000188:drug therapy* / Q000235:genetics; D004285:Dogs; D005029:Ethylenediamines / Q000627:therapeutic use*; D005260:Female; D007501:Iron / Q000032:analysis / Q000097:blood; D008099:Liver / Q000032:analysis / Q000473:pathology; D008107:Liver Diseases / Q000188:drug therapy / Q000235:genetics / Q000662:veterinary*; D008297:Male; D008664:Metal Metabolism, Inborn Errors / Q000188:drug therapy / Q000235:genetics / Q000662:veterinary*; D010375:Pedigree; D014266:Trientine / Q000627:therapeutic use*; D015032:Zinc / Q000032:analysis / Q000097:blood
D005029:Ethylenediamines; D003300:Copper; D007501:Iron; D015032:Zinc; D014266:Trientine